Evidence map›Paper›PMID 12789266›Full record

ArticleOncogene2003

Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.

James B DuHadaway, Wei Du, Scott Donover, Judith Baker, Ai-Xue Liu, Diane M Sharp, Alexander J Muller, George C Prendergast

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. BIN1 in cancer: biomarker and therapeutic target.Journal of cancer research and clinical oncology · 2023
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

James B DuHadawayLankenau Institute for Medical Research, Wynnewood, PA 19096, USA.
Wei Du
Scott Donover
Judith Baker
Ai-Xue Liu
Diane M Sharp
Alexander J Muller
George C Prendergast
Lankenau Institute for Medical Research · USDuPont (United States) · USGlaxoSmithKline (United Kingdom) · GB

Funding

ROLE OF RHO IN FARNESYLTRANSFERASE INHIBITOR RESPONSESR01CA082222 · NCI · WISTAR INSTITUTE · PI PRENDERGAST, GEORGE C · 1999 to 2008
$2.4M
NCI NIH HHS CA82222
6 · The paper itself

Abstract

Neoplastic transformation sensitizes many cells to apoptosis. This phenomenon may underlie the therapeutic benefit of many anticancer drugs, but its molecular basis is poorly understood. We have used a selective and potent farnesyltransferase inhibitor (FTI) to probe a mechanism of apoptosis that is peculiarly linked to neoplastic transformation. While nontoxic to untransformed mouse cells, FTI triggers a massive RhoB-dependent, p53-independent apoptosis in mouse cells that are neoplastically transformed. Here we offer evidence that the BAR adapter-encoding tumor suppressor gene Bin1 is required for this transformation-selective death program. Targeted deletion of Bin1 in primary mouse embyro fibroblasts (MEFs) transformed by E1A+Ras did not affect FTI-induced reversion, actin fiber formation, or growth inhibition, but it abolished FTI-induced apoptosis. The previously defined requirement for RhoB in these effects suggests that Bin1 adapter proteins act downstream or in parallel to RhoB in cell death signaling. The death defect in Bin1 null cells was significant insofar as it abolished FTI efficacy in tumor xenograft assays. p53 deletion did not phenocopy the effects of Bin1 deletion. However, MEFs transformed by SV40 large T antigen+Ras were also resistant to apoptosis by FTI, consistent with other evidence that large T inhibits Bin1-dependent cell death by a p53-independent mechanism. Taken together, the results define a function for Bin1 in apoptosis that is conditional on transformation stress. This study advances understanding of the functions of BAR adapter proteins, which are poorly understood, by revealing genetic interactions with an Rho small GTPase that functions in stress signaling. The frequent losses of Bin1 expression that occur in human breast and prostate cancers may promote tumor progression and limit susceptibility to FTI or other therapeutic agents that exploit the heightened sensitivity of neoplastic cells to apoptosis.

Indexed as

Adaptor Proteins, Signal TransducingNerve Tissue ProteinsActinsAdenovirus E1A ProteinsAlkyl and Aryl TransferasesAnimalsAntigens, Polyomavirus TransformingApoptosisApoptosis Regulatory ProteinsCarrier ProteinsCell DivisionCells, CulturedCell Transformation, NeoplasticEnzyme InhibitorsFarnesyltranstransferaseFibroblastsActinsAdaptor Proteins, Signal TransducingAdenovirus E1A ProteinsAlkyl and Aryl TransferasesAntigens, Polyomavirus TransformingApoptosis Regulatory ProteinsBFAR protein, humanBin1 protein, mouseCarrier ProteinsEnzyme InhibitorsFarnesyltranstransferaseL 744832Membrane ProteinsMethionineNerve Tissue ProteinsNuclear Proteinsras ProteinsrhoB GTP-Binding ProteinTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID12789266
OpenAlexW2083629160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.